Cancer News

FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment (07/18/2016)

The United States Food and Drug Administration (FDA) has placed a hold on a clinical trial, referred to as the ROCKET trial, due to side effects of the treatment that may be associated with 3 patient deaths. Chimeric antigen receptor (CAR) technology is an emerging treatment technique that has demonstrated significant effectiveness in the treatment … Continue reading "FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment"